CCDC51 Inhibitors
CCDC51 Inhibitors represent a collection of small molecule compounds that exert their inhibitory effects on the functional activity of CCDC51 by meticulously targeting specific components of the signaling pathways that CCDC51 is associated with. Rapamycin and its derivatives, Everolimus and Temsirolimus, anchor this group by forming a complex with FKBP-12, which in turn inhibits mTORC1, a key regulatory kinase whose activity is essential for the functional role of CCDC51. Similarly, Torin 1 and KU 0063794, both potent inhibitors of mTORC1 and mTORC2, contribute to this regulatory blockade, ensuring a comprehensive dampening of CCDC51 activity through the mTOR pathway. The PI3K/Akt/mTOR axis, a central conduit for numerous signaling cascades involved in cellular growth and metabolism, is also targeted by inhibitors such as LY 294002 and Wortmannin, which by hindering PI3K, indirectly impose a decrease in CCDC51 activity. Additionally, Perifosine disrupts this axis further downstream by preventing Akt activation, which subsequently diminishes mTOR activity and the associated functional role of CCDC51.
Expanding on the theme of targeting upstream regulators, Triciribine and Palomid 529 exert their effects by inhibiting Akt and the PI3K/Akt pathways respectively, each leading to an attenuated mTOR signaling and a consequent reduction in CCDC51 function. AZD8055's dual inhibition of mTORC1 and mTORC2 also culminates in a diminished CCDC51 activity, ensuring that the protein's function is mitigated through a broad spectrum of regulatory interference. The consistent theme among these inhibitors is the strategic diminution of CCDC51's activity by curtailing the upstream mTOR signaling, which is a pivotal pathway for the protein's functional involvement. This concerted inhibition by diverse yet specific chemical compounds ensures that the functional activity of CCDC51 is reliably and effectively decreased, rendering these inhibitors crucial tools in the exploration of CCDC51's role in cellular processes.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 is a potent inhibitor of both mTORC1 and mTORC2. It would decrease CCDC51's activity through the broad inhibition of mTOR signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is a specific inhibitor of mTOR (mammalian target of rapamycin). Since CCDC51 has been implicated in the mTOR signaling pathway, rapamycin would lead to the inhibition of this pathway, thereby diminishing the functional activity of CCDC51 by preventing its involvement in mTOR-mediated processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a potent inhibitor of PI3K (phosphoinositide 3-kinases). PI3K is upstream of mTOR signaling, which is related to CCDC51 activity. Inhibition of PI3K would dampen the mTOR pathway, leading to a reduction in CCDC51 functional activity associated with this signaling cascade. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor. It suppresses the PI3K/Akt/mTOR pathway, ultimately leading to a decrease in CCDC51 activity, as CCDC51 is a part of this signaling process. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine specifically inhibits Akt, which is downstream of PI3K and upstream of mTOR. By inhibiting Akt, triciribine would diminish the activity of mTOR and thereby indirectly decrease the functional activity of CCDC51 that is involved in the mTOR signaling pathway. | ||||||
Palomid 529 | 914913-88-5 | sc-364563 sc-364563A | 10 mg 50 mg | $300.00 $1000.00 | ||
Palomid 529 (P529) is an inhibitor that acts on both the mTOR and PI3K/Akt pathways. It would decrease CCDC51 activity indirectly by inhibiting the signaling pathways that facilitate its function. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus is an mTOR inhibitor. It works by binding to FKBP-12, forming a complex that inhibits mTORC1. As CCDC51's activity is related to the mTOR pathway, everolimus would result in a reduction of CCDC51 functional activity. | ||||||
Perifosine | 157716-52-4 | sc-364571 sc-364571A | 5 mg 10 mg | $188.00 $327.00 | 1 | |
Perifosine is an alkylphospholipid that inhibits Akt. By hindering Akt activation, it would indirectly lead to a reduction in mTOR activity and therefore a decrease in the functional activity of CCDC51, which is involved in the Akt/mTOR signaling pathway. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is a selective mTOR kinase inhibitor. It would lead to decreased CCDC51 activity by inhibiting mTOR signaling, which is a pathway where CCDC51 is implicated. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is a potent and selective inhibitor of mTORC1 and mTORC2. By inhibiting these complexes, AZD8055 would reduce the functional activity of CCDC51 by diminishing the mTOR signaling pathway that CCDC51 is a part of. | ||||||